Hiroiku Kawakami Selected Research

lipoarabinomannan (LAM)

5/2007

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroiku Kawakami Research Topics

Disease

4	Chronic Hepatitis B 01/2019 - 05/2007
3	Chronic Hepatitis C 02/2015 - 01/2006
1	Hepatitis 10/2013
1	Hepatitis C 06/2009
1	Infections 05/2007
1	Hemolytic Anemia 01/2007

Drug/Important Bio-Agent (IBA)

3	InterferonsIBA 01/2019 - 02/2015
3	NucleotidesIBA 01/2019 - 10/2013
3	NucleosidesIBA 01/2019 - 05/2007
3	Ribavirin (Virazole)FDA LinkGeneric 02/2015 - 01/2007
3	RNA (Ribonucleic Acid)IBA 10/2013 - 01/2006
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 01/2018
2	AntigensIBA 01/2019 - 01/2018
2	Hepatitis B e AntigensIBA 01/2018 - 10/2013
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	nasIBA 10/2013
1	Lamivudine (Epivir)FDA Link 05/2007
1	lipoarabinomannan (LAM)IBA 05/2007
1	Eicosapentaenoic AcidIBA 01/2007
1	Interferon-alpha (Interferon Alfa)IBA 01/2007

Therapy/Procedure

6	Therapeutics 01/2019 - 01/2007